Quantitative Analysis of a Parasitic Antiviral Strategy

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 3, 2004, Pages 1017-1020

  Kim, Hwijin ^a   Yin, John ^a,b  

^a University of Wisconsin Madison   (United States)

^b 3633 Engineering Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ARTICLE; CELL GROWTH; COMPUTER SIMULATION; DRUG RESISTANCE; PARASITE DEVELOPMENT; PRIORITY JOURNAL; VIROGENESIS; VIRUS REPLICATION; VIRUS STRAIN;

ALLOLEVIVIRUS; ANTIVIRAL AGENTS; CAPSID PROTEINS; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; ESCHERICHIA COLI; RNA, VIRAL; VIRUS REPLICATION; VIRUSES;

EID: 1442300069     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.3.1017-1020.2004     Document Type: Article

References (19)

1. Biebricher, C. K., M. Eigen, and W. C. Gardiner. 1985. Kinetics of RNA replication: competition and selection among self-replicating RNA species. Biochemistry 24:6550-6560.
2. Biebricher, C. K. 1987. Replication and evolution of short-chained RNA species replicated by Qβ replicase. Cold Spring Harbor Symp. Quant. Biol. 52:299-306.
3. Bull, J., A. Jacobson, M. Badgett, and I. Molineux. 1998. Viral escape from antisense RNA. Mol. Microbiol. 28:835-846.
4. Clercq, E. D. 2002. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discov. 1:13-25.
5. Coleman, J., A. Hirashima, Y. Inokuchi, P. J. Green, and M. Inouye. 1987. A novel immune system against bacteriophage infection using complementary RNA (micRNA). Nature 315:601-603.
6. Collier, A. C., et al. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N. Engl. J. Med. 334:1011-1018.
7. Domingo, E., A. Mas, E. Yuste, N. Pariente, S. Sierra, M. Gntiérrez-Rivas, and L. Menéndez-Arias. 2001. Virus population dynamics, fitness variations and the control of viral disease: an update. Prog. Drug Res. 57:77-115.
8. Eigen, M., C. K. Biebricher, M. Gebinoga, and W. C. Gardiner. 1991. The hypercycle. Coupling of RNA and protein biosynthesis in the infection cycle of an RNA bacteriophage. Biochemistry 30:11005-11018.
9. Eron, J. J., et al. 1995. Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200 to 500 CD4 cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
10. Grumet, R., J. C. Sanford, and S. A. Johnston. 1987. Pathogen-derived resistance to viral infection using a negative regulatory molecule. Virology 161:561-569.
11. Larder, B. A., P. Kellam, and S. D. Kemp. 1993. Convergent combination therapy can select viable mutidrug-resistant HIV-1 in vitro. Nature 365:451-453.
12. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
13. Lindemann, B. F., C. Klug, and A. Schwienhorst. 2002. Evolution of bacteriophage in continuous culture: a model system to test antiviral gene therapies for the emergence of phage escape mutants. J. Virol. 76:5784-5792.
14. Richman, D. D. 1994. Drug resistance in viruses. Trends Microbiol. 2:401-407.
15. Richman, D. D., T. Meng, S. A. Spector, M. A. Fischl, L. Resnick, and S. Lai. 1994. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J. Acquired Immune Defic. Syndr. 7:135-138.
16. Schwienhorst, A., and B. F. Lindemann. 1998. A novel vector for generating RNAs with defined 3′ ends and its use in antiviral strategies. BioTechniques 24:116-126.
17. Weissmann, C. 1974. The making of a phage. FEBS Lett. 40(Suppl.):S10-S18.
18. Werner, M. 1991. Kinetic and thermodynamic characterization of the interaction between Qβ-replicase and template RNA molecules. Biochemistry 30:5832-5838.
19. Zinder, N. D. (ed.). 1975. RNA phages. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.